20 results about "Particulate antigen" patented technology

The invention provides a solid-phase agglutination detection test paper card directly marked by antigens and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a conjugate formed by coupling a specific antigen and an inert carrier, the specific antigen is not a protein, and the specific antigen is specifically combined with an antibody to be detected. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.

The present disclosure provides a type A foot-and-mouth disease virus-like particle antigen assembled by VP2, VP3 and VP1 antigen proteins of an epidemic strain of type A foot-and-mouth disease virus. The type A foot-and-mouth disease virus VP2 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 1 or its degenerate sequence, the type A foot-and-mouth disease virus VP3 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 2 or its degenerate sequence, and the type A foot-and-mouth disease virus VP1 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 3 or its degenerate sequence.

The present application relates to the technical field of veterinary biological products, and particularly provides a porcine circovirus type 3 (PCV3) Cap protein and a related product thereof. The PCV3 Cap protein is an NLS region 8-16aa truncated Cap protein. The amino acid sequence of the Cap protein is as shown in SEQ ID NO: 2. The present application further provides a PCV3 virus-like particle antigen, which is the PCV3 Cap protein. The Cap protein is expressed at a higher level. A vaccine prepared from the antigen exhibits strong immunogenicity and provides excellent protective efficacy.

The invention belongs to the technical field of preparation of veterinary vaccines, and particularly relates to a Senecavirus type A nanoparticle antigen and application thereof in preparation of a nanoparticle vaccine. According to the invention, a general Th cell epitope is fused with a highly conservative B cell neutralizing epitope VP2150-160aa of a three-copy Senecavirus A capsid protein, and the fused recombinant protein is displayed on the surface of a nanoparticle, so that the Senecavirus A nanoparticle antigen is finally constructed. The Senecavirus A nanoparticle vaccine is prepared from the Senecavirus A nanoparticle antigen, and the Senecavirus A nanoparticle vaccine can display more antigens at a time, so that the immunogenicity of the vaccine can be improved, and the immune effect of the vaccine can be enhanced.

This invention relates to the field of Clostridium perfringens antigen technology, and particularly to a Clostridium perfringens α-toxin-ferritin nanoparticle antigen, its preparation method, and its application. The Clostridium perfringens α-toxin-ferritin nanoparticle antigen is assembled from αm2ST protein and FeSC protein. The αm2ST protein is expressed using an α-protein mutant expression plasmid, and the FeSC protein is expressed using a ferritin expression plasmid. The nucleotide sequence of the α-protein mutant expression plasmid is shown in SEQ ID NO: 1, and the nucleotide sequence of the ferritin expression plasmid is shown in SEQ ID NO: 2. The Clostridium perfringens α-toxin-ferritin nanoparticle antigen provided by this invention can effectively stimulate humoral and cellular immunity, providing a new approach for the development of Clostridium perfringens subunit vaccines.

The application discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. A homologous sequence of a porcine epidemic diarrhea virus spike protein is screened and fused with a monomer porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression amount or titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then unit point or multi-point mutation, and the expression amount and titer of the obtained mutant are both significantly improved. The application uses a silkworm or an AcMNPV-insect cell eukaryotic expression system to express a recombinant protein to obtain a self-assembled ferritin nanoparticle antigen with S protein antigen protein displayed on the surface of a porcine ferritin cage structure, and the vaccine prepared by using the prepared nanoparticle antigen can cause a broad neutralization of anti-porcine epidemic diarrhea virus antibodies and has the potential to become a universal porcine epidemic diarrhea virus vaccine with cross-immunity efficacy.

The invention belongs to the field of veterinary drugs, and relates to an infectious bronchitis nanoparticle antigen and a vaccine thereof. The avian infectious bronchitis nanoparticle antigen is a helicobacter pylori ferritin nanoparticle with an avian infectious bronchitis virus S1 protein fragment. The nanoparticle vaccine comprises an immunizing dose of the avian infectious bronchitis nanoparticle antigen and a pharmaceutically acceptable carrier. The vaccine has the excellent effects of being high in safety, good in immunogenicity, stable in batches and capable of providing complete protection for attacking the infectious bronchitis virus.

Embodiments of the present disclosure pertain to a composition that includes a particle, an antigen, and a modulator. The modulator may include, without limitation, an agonist, an activator of the immune system, or combinations thereof. The antigen may be operable to elicit an immune response in a subject against respiratory syncytial virus (RSV). Additional embodiments of the present disclosure pertain to methods of treating or preventing a respiratory infection in a subject by administering a composition of the present disclosure to the subject.

This application relates to the field of biomedicine. Specifically, it involves a fusion protein and compositions, kits, particulate antigens, vaccines, and pharmaceutical compositions. The present invention also relates to use of the fusion protein and the composition, the kit, and the particulate antigen comprising same in the preparation of a pharmaceutical composition or a vaccine. The particulate antigen is particularly suitable for the production and vaccination of a vaccine and has advantages in the prevention and / or treatment of viral infections.

The application belongs to the field of biological medicine, and particularly relates to a bivalent nanoparticle antigen for preventing respiratory syncytial virus infection and application thereof. The F protein sequences of two subtypes of RSVA and B and the human Ferritin protein sequence are connected in series, the post-F specific I and IV epitope sequences and the pre-F and post-F shared III epitope partial sequences are removed, and the bivalent antigen nanoparticle containing the new F protein of the two subtypes A and B is obtained through the self-assembly of the Ferritin protein. The bivalent nanoparticle antigen has a larger molecular weight, can effectively improve the immunogenicity of the antigen, stimulate the body to produce more neutralizing antibodies, and produce neutralizing antibodies against the two subtypes A and B of viruses, and is more broad-spectrum.

The present application relates to avian egg drop syndrome virus subunit nanoparticle antigen, the subunit nanoparticle antigen is assembled by avian egg drop syndrome virus Knob-HPF fusion protein; the protein sequence of the Knob-HPF fusion protein is sequentially composed of the Knob region of avian egg drop syndrome virus Fiber protein, linker and the N-terminal fragment of Helicobacter pylori Ferritin (HPF) from N-terminal to C-terminal; the Knob region of the avian egg drop syndrome virus Fiber protein is encoded by SEQ ID NO:1 or its degenerate sequence.The subunit nanoparticle antigen is spheroidal nanoparticle of 24-mer, antigen titer is high, and the prepared vaccine has good immunoprotective effect.

The invention relates to the field of protein detection, in particular to a method for detecting phosphorylated Tau-231 protein in urine of a patient with Alzheimer's disease, which comprises the following steps: firstly, immobilizing a non-phosphorylated anti-Tau-231 antibody on a magnetic particle microsphere, immobilizing a phosphorylated anti-Tau-p-231 antibody on a fluorescent microsphere, and then, immobilizing a phosphorylated anti-Tau-p-231 antibody on the fluorescent microsphere. Forming a sandwich compound of magnetic particle-antigen-fluorescent probe by the detected object; the method specifically comprises the following steps: using fresh morning urine; the method comprises the following steps: taking out 100 [mu] l of urine by using a pipette, and adding the urine into a 5.0 ml centrifugal tube in which a phosphorylated anti-Tau-p-231 antibody which is prefabricated with a fluorescence label and a non-phosphorylated anti-Tau-p-231 antibody which is connected with nano magnetic particle microspheres are prefabricated; 4.9 ml of a urine diluent is added to dilute the urine; repeatedly reversing and uniformly mixing, reacting at room temperature for 8-12 hours, and placing a reaction tube on a separation test tube rack with a magnet for more than 20 minutes; irradiating the test tube by using a highlighter with the wavelength of about 340nm in a dark environment to judge a result; finally, the purposes of early screening, early intervention and early diagnosis of the Alzheimer's disease are achieved.

This invention discloses a fusion protein, PEDV RBD nanoparticle antigen, its preparation method, and its applications. The fusion protein is obtained by fusing the receptor-binding domain of the porcine epidemic diarrhea virus (PEDV) Spike protein to the N-terminus of a ferritin monomer via a linker peptide. It can self-assemble into PEDV RBD nanoparticle antigens with an average diameter of approximately 15 nm. The nanoparticle antigens exhibit structural integrity, enabling high-density multivalent display of the RBD, and possess excellent antigenic activity, specificity, thermal stability, and biocompatibility, making them suitable for large-scale production. This invention provides a safe, infection-free, and easily industrialized vaccine strategy for addressing PEDV infection. It can be further expanded for applications in veterinary vaccine formulation optimization and the research and development of diagnostic antigens and reagents, demonstrating good practicality and industrialization prospects.

The invention relates to the technical field of veterinary biological products, and particularly provides a porcine circovirus type 3 Cap protein and related products thereof. And the Cap protein of the porcine circovirus type 3 (PCV3) is a truncated Cap protein of 8-16aa in an NLS region. The amino acid sequence of the Cap protein is as shown in SEQ ID NO. 2. The invention also provides a PCV3 virus-like particle antigen which is the Cap protein of the porcine circovirus type 3 (PCV3). The Cap protein is expressed at a higher level. A vaccine prepared from the antigen is good in immunogenicity and has very good protective force.

The present application relates to the technical field of virology, more particularly to O-type foot-and-mouth disease virus-like particle antigen and its preparation method and application. The O-type foot-and-mouth disease virus structural protein is constructed, and the recombinant expression vector comprises a Sumo-VP1 sequence, a Sumo-VP3 sequence, a Sumo-VP0 sequence and a chaperone sequence; the recombinant expression vector is transformed into a genetically engineered bacterium, and Sumo-VP1 protein, Sumo-VP3 protein, Sumo-VP0 protein and chaperone protein are expressed; the initial extraction solution is obtained by crushing; the purified extraction solution is obtained by purification; the self-assembled O-type foot-and-mouth disease virus-like particle antigen is obtained by enzyme cutting and removal of Sumo enzyme. The present application improves the soluble expression proportion and overall expression amount of the target protein in the supernatant by optimizing the construction mode and transformation strategy of the foot-and-mouth disease structural protein, and overcomes the technical bottleneck that the supernatant expression amount of the existing E. coli expression system is low and the inclusion body is prone to be formed.

The invention relates to the technical field of veterinary biological products, and particularly provides a porcine circovirus type 3 Cap protein and a porcine circovirus type 3 subunit vaccine. The amino acid in the NLS region of the Cap protein of the porcine circovirus type 3 (PCV3) has 12R-K substitution, and 75-76aa (AI) is substituted into PGGGSNPR. The amino acid sequence of the Cap protein is as shown in SEQ ID NO. 4. The invention also provides a PCV3 virus-like particle antigen which is the Cap protein of the porcine circovirus type 3 (PCV3). The virus-like particle vaccine comprises an immunizing dose of the PCV3 virus-like particle antigen and a pharmaceutically acceptable carrier. According to the invention, the correct assembly of the PCV3 virus-like particles is promoted, and the stability of the protein is improved.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a hypersensitive antibody detection method and kit based on collaborative optimization of magnetic particle coating, ALP cascade signal amplification and EDTA gradient washing. According to the technical scheme, carboxylated magnetic particles are activated through EDC / NHS and then covalently coupled with a target antigen, a signal is amplified through a cascade reaction of a biotinylated second antibody and ALP coupled streptavidin, the ALP catalytic efficiency is enhanced through a 4-MUP substrate containing 1 mM MgCl2, and gradient washing is conducted through a washing solution containing EDTA to eliminate background interference. The limitation of single module optimization is broken through, the signal / background ratio is larger than or equal to 50, and the detection limit is smaller than or equal to 0.5 ng / mL. Compared with the prior art, the sensitivity is improved by 10-20 times, and the antigen binding stability of the magnetic particles is remarkably improved (the magnetic particles are stored for 12 months at the temperature of 2-8 DEG C, and the performance degradation is smaller than or equal to 10%). The kit is suitable for early infection of pathogens such as mycoplasma pneumoniae and hypersensitivity detection of tumor markers.

The invention relates to a PCSK9 vaccine, in particular to preparation and application of a particle antigen. The present invention provides an immunogenic complex comprising (a) a PCSK9 immunogenic fragment and (b) a carrier protein. The PCSK9 vaccine disclosed by the invention has outstanding immunogenicity and can be used for effectively preventing and treating PCSK9 related diseases.